00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
23:29 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Reata reports additional Phase II data for bardoxolone in Alport syndrome

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported additional data from 30 patients with chronic kidney disease (CKD) caused by Alport syndrome in the open-label Phase II portion of the Phase II/III CARDINAL trial showing that once-daily oral...
21:04 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

Reata reports Phase II data for bardoxolone methyl in CKD

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported data from 30 patients with chronic kidney disease (CKD) caused by Alport syndrome in the open-label Phase II portion of the Phase II/III CARDINAL trial showing that once-daily oral bardoxolone...
22:44 , Jul 24, 2017 |  BC Extra  |  Clinical News

Reata gains as bardoxolone study moves to Phase III

Reata Pharmaceuticals Inc. (NASDAQ:RETA) gained $4.37 (14%) to $35.47 on Monday after saying it will move ahead to the Phase III portion of the Phase II/III CARDINAL study of bardoxolone methyl (RTA 402) to treat...
22:59 , Mar 2, 2017 |  BC Week In Review  |  Clinical News

Bardoxolone methyl: Ph II/III started

Reata began a U.S. Phase II/III trial to evaluate bardoxolone in 210 patients with the rare form of chronic kidney disease (CKD). The open-label Phase II portion will enroll up to 30 patients. Adult patients...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

Bardoxolone methyl: Phase III started

Reata began the double-blind, placebo-controlled, international Phase III CATALYST trial to evaluate oral bardoxolone methyl once daily for 24 weeks plus vasodilator therapy in 130-200 patients with connective tissue disease-associated PAH. Patients will initially receive...
00:56 , May 27, 2016 |  BC Extra  |  Financial News

Reata surges after IPO

Reata Pharmaceuticals Inc. (NASDAQ:RETA) gained $2.07 (19%) to $13.07 in its first day of trading Thursday after it raised $60.5 million through the sale of 5.5 million shares at $11 in an IPO underwritten by...
08:00 , Jan 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2); heme oxygenase decycling 1 (HMOX1; HO-1; Hsp32)

Inflammation INDICATION: Inflammation Cell culture and mouse studies identified two activators of the anti-inflammatory NFE2L2/HMOX1 pathway that could help treat inflammation. Chemical synthesis and hemoglobin-based assays of compounds linking diverse NFE2L2 inducers to cobalt-carbon monoxide complexes...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

Bardoxolone methyl: Preliminary Phase II data

Preliminary data from 24 PAH patients on stable doses of background PAH therapy in the double-blind, dose-escalation, U.S. Phase II LARIAT trial showed that once-daily 2.5, 5 and 10 mg oral bardoxolone methyl led to...
07:00 , Jun 4, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: An undetermined target

Cancer INDICATION: Prostate cancer In vitro and mouse studies suggest lactam-based analogs of oleanolic acid could help treat prostate and other cancers. Chemical synthesis and in vitro testing of a series of olean-28,13β-lactams identified a lead compound...